Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
3 drugs in development
By Therapeutic Area
top 2
R&D Momentum
70/100
Pipeline Velocity
37/100
Trial Completion Rate
83/100
Pipeline Concentration
38/100
Pipeline Freshness
30/100
Strategic Signals
Activity
Last 14 days
Effectiveness of Eccentric Cycling Exercise in Ambulatory Rehabilitation for Patients With Cardiopulmonary Diseases: A Pragmatic Randomized Controlled Trial
RENEW-SHCS: A Phase 1 Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Env Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted, in ARV-treated Adults Living With HIV Enrolled in the SHCS and to Restimulate and Newly Prime Antibody Responses.
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Regulatory
Oxygen — OXYGEN, USP
Application NDA206023
Oxygen — NITROUS OXIDE, USP
Application NDA206009
Oxygen — OXYGEN, USP
Application NDA205986
Oxygen — OXYGEN, USP
Application NDA205889
Oxygen — OXYGEN, USP
Application NDA205862
Oxygen — OXYGEN, USP
Application NDA205865
Oxygen — OXYGEN, USP
Application NDA205849
Oxygen — HELIUM, USP
Application NDA205843
Oxygen — OXYGEN, USP
Application NDA205840
Oxygen — OXYGEN, USP
Application NDA205820
Oxygen — OXYGEN, USP
Application NDA205767
Oxygen — OXYGEN, USP
Application NDA205818
Oxygen — OXYGEN, USP
Application NDA205817
Oxygen — CARBON DIOXIDE, USP
Application NDA205764
Oxygen — OXYGEN, USP
Application NDA205737
Oxygen — OXYGEN, USP
Application NDA205712
Oxygen — MEDICAL AIR, USP
Application NDA211270
Oxygen — OXYGEN, USP
Application NDA211739
Oxygen — OXYGEN, USP
Application NDA212314
Oxygen — OXYGEN, USP
Application NDA217500
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)